Effect of progesterone combined with chemotherapy on epithelial ovarian cancer

Chinese Medical Journal

Volumn 116, Issue 3, 2003, Pages 388-391

  Chen, Xiaojun ^a   Feng, Youji ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Chemotherapy; Ovarian neoplasm; Progesterone

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; PLATINUM DERIVATIVE; PROGESTERONE;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG CHOICE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PROGNOSIS; STATISTICAL ANALYSIS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGESTERONE; SURVIVAL RATE;

EID: 0037358917     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Zhang XY, Zhu RL. Clinical Gynecological Oncology, vol., 1st ed. Shanghai: Publishing company of Shanghai Medical University, 1993:152-154.
2. Emons G, Ortmann O, Teichert HM, et al. Luteinizing hormone-releasing hormone agonist triptorelin in combination with cytotoxic chemotherapy in patients with advanced ovarian carcinoma. A prospective double blind randomized trial. Cancer 1996; 78: 1452-1460.
3. Neijt JP. The place of combination chemotherapy in the treatmeant of advanced ovarian cancer. In: Proc. of the 17th Study Group of the Royal College of Obstet. Gynaecol. in conjection with the H. Harris Memorial Trust. London: Chameleon Press; 1987:329-341.
4. Ver Der Vange N, Greggi S, Burger CW, et al. Experience with hormonal therapy in advanced epithelial ovarian cancer. Acta Oncol 1995;34:813-820.
5. Annegers JT, Strom H, Decker DG, et al. Ovarian cancer: incidence and case-control study. Cancer 1979;43:723-729.
6. Schneider HP, Birkhauser M. Dose HRT modify risk of gunecological cancer? Int J Fertil Menopausal Stud 1995; 40 (Suppl 1) :40-53.
7. Slotman BJ. Rational for the use of endocrine therapy in ovarian cancer [Dissertation]. Amsterdam: Free University Amsterdam; 1990.
8. Feng YJ, Jin ZJ, Zhang XY, et al. Mydroxyprogesterone effect on C-erb B-2 protein expression and cell histology in the human ovarian 3AO cancer cell line. Acta Acad Med Shanghai 1994;2: 38-40.
9. Bu SZ, Yin DL, Ren XH, et al. Progesterone induces apoptosis and up-regulation of p53 expression in human ovarian carcinoma cell lines. Cancer 1997;79:1944-1950.
10. Feng YJ, Jin ZJ, Zhang XY, et al. A preliminary study of the inhibitory effects of medroxyprogesteroneon human epithelial ovarian cancer. Chin J Obstet Gynecol 1995;30:93-95.
11. Malick S, Horwitz SB. A role for progesterone in multidrug resistance. Estrogens, Progestins, and Their Antagnists [Volume 2]. In: Parlik EJ, eds. Boston: Birkhauser; 1996:123-151.
12. Jikikara H, Terada N, Yamamoto R, et al. Inhibitory effect of medroxyprogesterone acetate on angiogenesis induced by human endormetrial cancer. Am J Obstet Gynecol 1992;167:207-211.
13. Xie SZ, Gu MJ, Cheng YP. Inhibitory effect of medroxyprogesterone acetate on angiogenesis induced by malignant neoplasm. Chin J Obstet Gynecol 1998;33:113-114.
14. Metherall JE, Li H, Waugh K. Role of multidrug resistance P-Glycoproteins in Cholesterol Biosynthesis. J Biol Chem 1996; 271:2634-2640.
15. Zimnisiki SJ, Garola RE, Fendl S, et al. Endocrine characterization of human ovarian carcinoma (BG-1) established in nude mice. Steriod 1989;54:593-606.
16. Feng YJ, Zhang XY, Ge BQ, et al. Gonadotropins stimulates the proliferation of human epithelial ovarian cancer cell. Chin J Obstet Gynecol 1996;31:166-168.
17. Kammerman S, Demopoulos RI, Raphael C, et al. Gonadotropic hormone binding to human ovarian tumors. Hum Pathology 1981; 12(Suppl):886-890.
18. Menetta A, Liao S, Gamboa-Vujicic G, et al. Inhibition of growth of human ovarian cancer in nude mice by luteinizing hormone-releasing hormone antagonist cetrorelix (SB-85). Fertil Steril 1995;63:282-287.
19. Erickson LD, Hartmann LC, Su JQ, et al. Cyclophosphamide, cisplatin, and leuprolide acetate in patients with debulked stage III or IV ovarian carcinoma. Gynecol Oncol 1994;54:196-200.